Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 23, 2009

View Archived Issues

CSIR claims the discovery of novel anticancer agents

Novel PAPR inhibitors for the treatment of cancer described by Italian scientists

Positive modulators of nAChR in early development at NeuroSearch

Lundbeck discloses novel MCH-R1 ligands as antidepressants

Novartis presents novel PI3K inhibitors for the treatment of asthma

CDX-011 shows promising efficacy in advanced breast cancer patients

SS-1020, a new anti-estrogen candidate for treatment and prevention of breast cancer

AZD-1152 displays safety and efficacy in AML phase I/II trial

Unigene selects obesity drug UGP-281 as lead compound for development

Novel enzyme replacement therapy for Fabry disease in preclinical development

Fusion protein ACE-435 shows promise in cancer-induced cachexia therapy

UCB reports initial results for certolizumab pegol in Crohn's disease

BioDelivery Sciences presents phase II pain trial results for BEMA buprenorphine

Dual orexin receptor antagonist almorexant meets primary phase III endpoint

Vernakalant meets primary endpoint in European comparator study

Taro commences clinical trials with T-2007

Flamel initiates phase IIa IFN-alpha-2b XL trial in patients with chronic HCV

Ista submits supplemental NDA to FDA for once-daily XiDay

ChemoCentryx initiates phase II CCX-354 trial in rheumatoid arthritis

European CHMP recommends marketing authorization of Amgen's Prolia for osteoporosis

Ambit and Astellas to jointly develop and commercialize FLT3 kinase inhibitors

European CHMP recommends approval of Cangene's MAA for ImmunoGam

Cardium reports results from 10-year follow-up study of diabetic patients with foot ulcer

Myriad Pharmaceuticals to acquire Javelin Pharmaceuticals, including Dyloject

Seattle Genetics and GSK sign agreement for antibody-drug conjugate technology

Medicago reports phase I results for its avian flu pandemic vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...